The clinical trial of atezolizumab against various malignant tumors performed by Herbst et al. [11] showed that patients with high PD-L1 expression of tumor-infiltrating lymphocytes but not tumor as determined by immunostaining using the SP142 clone, were more responsive to atezolizumab compared to the patients with low PD-L1 expression of tumor-infiltrating lymphocyte. This evidence concerns the gene CD274 and cancer.